Regencell Bioscience (NASDAQ:RGC) Stock Price Down 4.4% – Here’s Why

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) dropped 4.4% on Thursday . The company traded as low as $19.75 and last traded at $19.5450. Approximately 11,985 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 282,055 shares. The stock had previously closed at $20.45.

More Regencell Bioscience News

Here are the key news stories impacting Regencell Bioscience this week:

• Negative Sentiment: Multiple law firms issued reminders and deadline alerts on June 11-12 about a pending securities class action against Regencell Bioscience, with investors urged to seek lead-plaintiff status by June 23, 2026. The repeated legal notices may weigh on sentiment by reinforcing concerns over the company’s disclosures and possible liabilities. Article: RGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit
• Negative Sentiment: Pomerantz LLP said it has filed a class action against Regencell Bioscience and certain officers, seeking damages for alleged violations of federal securities laws. A filed lawsuit can increase legal overhang and uncertainty for investors. Article: Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers – RGC
• Negative Sentiment: One alert described the case as involving an alleged DOJ subpoena and market-manipulation investigation, which could further damage investor confidence if those claims gain traction. Article: Lost Money on Regencell Bioscience Holdings Limited (RGC)? Join Class Action Suit Seeking Recovery – Contact SueWallSt
• Neutral Sentiment: Several other firms, including Faruqi & Faruqi, Glancy Prongay Wolke & Rotter, Bragar Eagel & Squire, and The Gross Law Firm, also circulated notices about the same lawsuit and deadline. These are largely duplicative updates that mostly keep the legal issue in the spotlight. Article: RGC SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Regencell Bioscience presently has an average rating of “Sell”.

Regencell Bioscience Stock Down 4.4%

The company has a 50-day simple moving average of $26.77 and a 200 day simple moving average of $25.61.

Regencell Bioscience (NASDAQ:RGC) last issued its quarterly earnings results on Friday, May 8th. The company reported $0.00 EPS for the quarter.

Institutional Trading of Regencell Bioscience

Several institutional investors have recently modified their holdings of RGC. Squarepoint Ops LLC acquired a new stake in shares of Regencell Bioscience during the 2nd quarter worth approximately $1,701,000. BNP Paribas Financial Markets acquired a new stake in shares of Regencell Bioscience during the 2nd quarter worth approximately $768,000. XTX Topco Ltd acquired a new stake in shares of Regencell Bioscience during the 3rd quarter worth approximately $598,000. Bank of America Corp DE grew its holdings in shares of Regencell Bioscience by 59,113.8% during the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after purchasing an additional 17,143 shares in the last quarter. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of Regencell Bioscience during the 4th quarter worth approximately $275,000. Institutional investors and hedge funds own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.